Pharsight

Adrenalin patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9295657 PAR STERILE PRODUCTS Epinephrine formulations
Mar, 2035

(10 years from now)

US9119876 PAR STERILE PRODUCTS Epinephrine formulations
Mar, 2035

(10 years from now)

US10130592 PAR STERILE PRODUCTS Epinephrine formulations
Mar, 2035

(10 years from now)

Adrenalin is owned by Par Sterile Products.

Adrenalin contains Epinephrine.

Adrenalin has a total of 3 drug patents out of which 0 drug patents have expired.

Adrenalin was authorised for market use on 07 December, 2012.

Adrenalin is available in solution;intramuscular, intravenous, subcutaneous dosage forms.

Adrenalin can be used as emergency treatment of allergic reactions (type i), including anaphylaxis.

The generics of Adrenalin are possible to be released after 13 March, 2035.

Drugs and Companies using EPINEPHRINE ingredient

Market Authorisation Date: 07 December, 2012

Treatment: Emergency treatment of allergic reactions (type i), including anaphylaxis

Dosage: SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS

How can I launch a generic of ADRENALIN before it's drug patent expiration?
More Information on Dosage

ADRENALIN family patents

Family Patents